LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-12. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Ian Goldin professor at University of Oxford, author of over twenty books and 60 scholarly academic monographs, founding director of the Oxford Martin School at the University of Oxford; currently the director of the Oxford Martin Research Programmes on Technological and Economic Change, Future of Work and Future of Development; also Professor of Globalisation and Development and holds a professorial fellowship at Balliol College at the University of Oxford; was principal economist at the European Bank for Reconstruction and Development (EBRD) in London, and program director at the OECD in Paris, where he directed the Development Centre's Programs on Trade, Environment and Sustainable Development; was chief executive and managing director of the Development Bank of Southern Africa (DBSA); served as adviser to President Nelson Mandela; Louis Golding novelist Lawrence Goldman (b.1957) ; historian, academic, Executive Editor of History Reclaimed, journalist; has written for Daily Mail, The Guardian, The Daily Telegraph, was director of the Oxford Dictionary of National Biography and of the Institute of Historical Research, University of London. Vivien Goldman British author and academic of German Jewish ancestry, focusing on the historiography, Praxis (process), dialectic and epistemology of punk rock, dub, and reggae.
Some or all of these measurements are also carried out (usually about twice a year for routine cases) on individuals taking certain medications, such as anticonvulsants, to ensure that these medications are not adversely impacting the person's liver.
=== Miniature ion trap mass analyzer === Ion traps include quadrupole ion traps or Paul trap, Fourier transform ion cyclotron resonance or Penning trap and newly developed orbitrap. However, Paul trap receives a great focus from researchers for a MMS because of its distinct advantages over other mass analyzers for building MMS. One of the benefits is that ion traps can work at much higher pressures than beam type mass analyzers and can be simplified with different geometry for the ease of fabrication. For example, a miniature quadrupole ion trap mass analyzers, such as cylindrical ion trap, linear ion trap, rectilinear ion trap), can operate at several mTorr in contrast to 10−5 Torr or less for other analyzers and it is able to perform MS/MS in a single device with minimum size of electronics system. Nevertheless, as the size gets smaller, it is hard to maintain the electric field shape and precise configuration and will negatively affect ion motion. The goal is to make the trap smaller without losing ion capacity. Tridion-9 mass spectrometer with toroidal ion trap is designed with a doughnut-shaped volume that can hold up to 400 times more ions. The outstanding result is achieved as the radius is reduced to one-fifth of a conventional laboratory ion trap while maintaining the ion capacity.
Sources: en.wikipedia.org
Another use for nuclear magnetic resonance is data acquisition in the petroleum industry for petroleum and natural gas exploration and recovery. Initial research in this domain began in the 1950s, however, the first commercial instruments were not released until the early 1990s. A borehole is drilled into rock and sedimentary strata into which nuclear magnetic resonance logging equipment is lowered. Nuclear magnetic resonance analysis of these boreholes is used to measure rock porosity, estimate permeability from pore size distribution and identify pore fluids (water, oil and gas). These instruments are typically low field NMR spectrometers. NMR logging, a subcategory of electromagnetic logging, measures the induced magnet moment of hydrogen nuclei (protons) contained within the fluid-filled pore space of porous media (reservoir rocks). Unlike conventional logging measurements (e.g., acoustic, density, neutron, and resistivity), which respond to both the rock matrix and fluid properties and are strongly dependent on mineralogy, NMR-logging measurements respond to the presence of hydrogen. Because hydrogen atoms primarily occur in pore fluids, NMR effectively responds to the volume, composition, viscosity, and distribution of these fluids, for example oil, gas or water. NMR logs provide information about the quantities of fluids present, the properties of these fluids, and the sizes of the pores containing these fluids. From this information, it is possible to infer or estimate:
== Toxicological data == The toxicological effects of 2,6‑dichloro‑1,4‑benzoquinone (2,6‑DCBQ) have been investigated in several experimental models. In mice, a 28‑day exposure study reported renal injury following 2,6‑DCBQ exposure. Proposed mechanisms include the activation of inflammatory pathways, oxidative stress, and apoptosis. Toxicity has also been examined in embryonic zebrafish, where exposure resulted in acute and developmental toxicity. Observed effects included impaired cardiovascular development and alterations in molecular signaling pathways. Studies using human cell lines have also reported cytotoxic effects. In kidney cells, exposure primarily induces anoikis, a form of apoptosis associated with loss of cell–matrix interactions. In human colon epithelial and liver cells, 2,6‑DCBQ exposure increases the production of reactive oxygen species (ROS). Prolonged low‑dose exposure in normal colon and liver cell lines has been associated with oxidative stress, DNA damage, and molecular changes that may indicate a potential role in carcinogenesis. In cell culture systems, the half‑life of 2,6‑DCBQ has been estimated to be less than one hour, and the parent compound appears to exhibit greater cytotoxicity than its transformation product.
Ir-catalyzed Lys and N-terminus (reductive) alkylation Imines formed from the condensation of aldehydes with lysines or the N-terminus can be reduced efficient by a water-stable [Cp*Ir(bipy)(H2O)]SO4 complex in the presence of formate ions (serving as the hydride source). The reaction happens readily under physiologically relevant conditions and results in high conversion for various aromatic aldehydes.
The probability that an event or difference occurred by chance alone. In clinical trials, the level of statistical significance depends on the number of participants studied and the observations made, as well as the magnitude of differences observed. (NLM) Study endpoint
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.